APIs and Excipients

Characterizing APIs is Essential for Combo Drug Formulations

March 02, 2020

Formulating fixed-dose combination drugs proves more complex than simply adding one ingredient to another.

Bovine Heparin Meets Acceptable Impurity Levels

February 17, 2020

An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.

MilliporeSigma and ReForm Collaborate on Excipient Commercialization

February 13, 2020

The companies have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.

Pharmaceutical Technology's In the Lab eNewsletter

Antibody Development Made Easier with Synthetic Biology

February 05, 2020

Synthetic biology can help researchers circumvent the challenges of traditional methods of antibody generation.

The Search for Transparency in Excipient Sourcing

February 02, 2020

Researching excipient grades and sources, as well as screening suppliers and materials, form the basis of programs to mitigate risk.

Daiichi Sankyo Licenses ERS Genomics’ CRISPR Gene Editing Tech

January 31, 2020

Pharmaceutical Technology's In the Lab eNewsletter

The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.

Otsuka, PhoreMost Team Up for Drug Discovery

January 31, 2020

Pharmaceutical Technology's In the Lab eNewsletter

Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.

The new GMP conditioning product offering is designed to support clinical phase and commercialization stages of cell and gene therapy production.